Candidate Drug Kills Solid Tumors by Blocking Mitochondrial Respiration
By LabMedica International staff writers Posted on 03 Mar 2014 |
Image: Transmission electron micrograph of a cell mitochondrion (Photo courtesy of the University of California, San Diego).
Swedish researchers have developed a candidate low molecular weight drug that kills metabolically stressed cancer cells by interfering with the action of their mitochondria.
In solid tumors, there are areas with poor vascular supply where cancer cells divide more slowly due to a lack of oxygen and nutrients. When other tumor tissue is killed by chemo- or radiotherapy, theses dormant cells begin to grow and regenerate the tumor.
Investigators at Karolinska Institutet (Stockholm, Sweden) and the biotechnology company Vivolux AB (Uppsala, Sweden) have been looking for new drug candidates that could be used for the treatment and complete destruction of solid tumors. To this end, they employed spheroid cultures of HCT116 colon cancer cells to screen a diverse chemical library in order to find compounds with cytotoxic activity in core, hypoxic, regions of solid tumors.
They reported in the February 18, 2014, online edition of the journal Nature Communications that the screen had identified the compound VLX600, which demonstrated anticancer activity with a large therapeutic window both in vitro and in vivo. VLX600 showed enhanced cytotoxic activity under conditions of nutrient starvation and its anticancer activity was associated with reduced mitochondrial respiration, which led to deficient mitochondrial energy production and tumor cell death.
"We have identified a small molecule that we call VLX600, which in various in vitro and in vivo models has proven effective against dormant colon cancer cells that are otherwise very difficult to treat. VLX600 is a mild inhibitor of mitochondrial respiration, and we have found that dormant cancer cells have a limited possibility to compensate decreased mitochondrial function by increased glycolysis. The dormant cancer cells therefore die by starvation," said senior author Dr. Stig Linder, professor of experimental oncology at Karolinska Institutet.
Related Links:
Karolinska Institutet
Vivolux AB
In solid tumors, there are areas with poor vascular supply where cancer cells divide more slowly due to a lack of oxygen and nutrients. When other tumor tissue is killed by chemo- or radiotherapy, theses dormant cells begin to grow and regenerate the tumor.
Investigators at Karolinska Institutet (Stockholm, Sweden) and the biotechnology company Vivolux AB (Uppsala, Sweden) have been looking for new drug candidates that could be used for the treatment and complete destruction of solid tumors. To this end, they employed spheroid cultures of HCT116 colon cancer cells to screen a diverse chemical library in order to find compounds with cytotoxic activity in core, hypoxic, regions of solid tumors.
They reported in the February 18, 2014, online edition of the journal Nature Communications that the screen had identified the compound VLX600, which demonstrated anticancer activity with a large therapeutic window both in vitro and in vivo. VLX600 showed enhanced cytotoxic activity under conditions of nutrient starvation and its anticancer activity was associated with reduced mitochondrial respiration, which led to deficient mitochondrial energy production and tumor cell death.
"We have identified a small molecule that we call VLX600, which in various in vitro and in vivo models has proven effective against dormant colon cancer cells that are otherwise very difficult to treat. VLX600 is a mild inhibitor of mitochondrial respiration, and we have found that dormant cancer cells have a limited possibility to compensate decreased mitochondrial function by increased glycolysis. The dormant cancer cells therefore die by starvation," said senior author Dr. Stig Linder, professor of experimental oncology at Karolinska Institutet.
Related Links:
Karolinska Institutet
Vivolux AB
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples